Found: 157
Select item for more details and to access through your institution.
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
- Published in:
- Journals of Gerontology Series A: Biological Sciences & Medical Sciences, 2024, v. 79, n. 2, p. 1, doi. 10.1093/gerona/glad181
- By:
- Publication type:
- Article
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes.
- Published in:
- Journal of Personalized Medicine, 2023, v. 13, n. 5, p. 747, doi. 10.3390/jpm13050747
- By:
- Publication type:
- Article
Fasting Proinsulin Independently Predicts Incident Type 2 Diabetes in the General Population.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 7, p. 1131, doi. 10.3390/jpm12071131
- By:
- Publication type:
- Article
Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.888110
- By:
- Publication type:
- Article
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.786767
- By:
- Publication type:
- Article
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Published in:
- Drugs in R&D, 2017, v. 17, n. 3, p. 441, doi. 10.1007/s40268-017-0201-0
- By:
- Publication type:
- Article
HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- Published in:
- Cardiovascular Diabetology, 2019, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12933-019-0942-x
- By:
- Publication type:
- Article
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
- Published in:
- Nephrology Dialysis Transplantation, 2024, v. 39, n. 3, p. 414, doi. 10.1093/ndt/gfad183
- By:
- Publication type:
- Article
The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan.
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 10, p. 2289, doi. 10.1093/ndt/gfad078
- By:
- Publication type:
- Article
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 5, p. 1260, doi. 10.1093/ndt/gfac280
- By:
- Publication type:
- Article
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 4, p. 894, doi. 10.1093/ndt/gfac198
- By:
- Publication type:
- Article
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 9, p. 1647, doi. 10.1093/ndt/gfab335
- By:
- Publication type:
- Article
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 8, p. 1461, doi. 10.1093/ndt/gfab237
- By:
- Publication type:
- Article
Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 7, p. 1375, doi. 10.1093/ndt/gfac012
- By:
- Publication type:
- Article
Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 6, p. 1198, doi. 10.1093/ndt/gfab296
- By:
- Publication type:
- Article
Precision medicine approaches for diabetic kidney disease: opportunities and challenges.
- Published in:
- Nephrology Dialysis Transplantation, 2021, v. 36, p. 3, doi. 10.1093/ndt/gfab045
- By:
- Publication type:
- Article
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 9, p. 1570, doi. 10.1093/ndt/gfz064
- By:
- Publication type:
- Article
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 2, p. 274, doi. 10.1093/ndt/gfz290
- By:
- Publication type:
- Article
Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, p. ii38, doi. 10.1093/ndt/gfaa013
- By:
- Publication type:
- Article
Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, p. i1, doi. 10.1093/ndt/gfz282
- By:
- Publication type:
- Article
Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, n. 1, p. 138, doi. 10.1093/ndt/gfy217
- By:
- Publication type:
- Article
Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, n. 12, p. 2015, doi. 10.1093/ndt/gfz033
- By:
- Publication type:
- Article
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, n. 10, p. 1699, doi. 10.1093/ndt/gfy159
- By:
- Publication type:
- Article
Immune-unreactive urinary albumin as a predictor of cardiovascular events: the Hortega Study.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, n. 4, p. 633, doi. 10.1093/ndt/gfy087
- By:
- Publication type:
- Article
Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease.
- Published in:
- Nephrology Dialysis Transplantation, 2018, v. 33, n. 11, p. 2005, doi. 10.1093/ndt/gfx350
- By:
- Publication type:
- Article
Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 6, p. 779, doi. 10.3390/jcm8060779
- By:
- Publication type:
- Article
Competing-Risk Analysis of Death and End Stage Kidney Disease by Hyperkalaemia Status in Non-Dialysis Chronic Kidney Disease Patients Receiving Stable Nephrology Care.
- Published in:
- Journal of Clinical Medicine, 2018, v. 7, n. 12, p. 499, doi. 10.3390/jcm7120499
- By:
- Publication type:
- Article
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.
- Published in:
- Journal of Diabetes Research, 2022, p. 1, doi. 10.1155/2022/9998891
- By:
- Publication type:
- Article
Albuminuria and markers for cardiovascular risk in 12-year-olds from the general Dutch population: a cross-sectional study.
- Published in:
- European Journal of Pediatrics, 2023, v. 182, n. 11, p. 4921, doi. 10.1007/s00431-023-05152-4
- By:
- Publication type:
- Article
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
- Published in:
- Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02180-8
- By:
- Publication type:
- Article
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01949-7
- By:
- Publication type:
- Article
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01916-2
- By:
- Publication type:
- Article
Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Non-adherence to cardiometabolic medication as assessed by LC-MS/MS in urine and its association with kidney and cardiovascular outcomes in type 2 diabetes mellitus.
- Published in:
- Diabetologia, 2024, v. 67, n. 7, p. 1283, doi. 10.1007/s00125-024-06149-w
- By:
- Publication type:
- Article
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
- Published in:
- Diabetologia, 2024, v. 67, n. 1, p. 3, doi. 10.1007/s00125-023-06015-1
- By:
- Publication type:
- Article
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
- Published in:
- Diabetologia, 2022, v. 65, n. 7, p. 1085, doi. 10.1007/s00125-022-05694-6
- By:
- Publication type:
- Article
Lipoprotein particle sizes and incident type 2 diabetes: the PREVEND cohort study.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS Program.
- Published in:
- Diabetologia, 2021, v. 64, n. 11, p. 2402, doi. 10.1007/s00125-021-05524-1
- By:
- Publication type:
- Article
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 10, p. 2147, doi. 10.1007/s00125-021-05512-5
- By:
- Publication type:
- Article
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
- Published in:
- Diabetologia, 2020, v. 63, n. 6, p. 1128, doi. 10.1007/s00125-020-05133-4
- By:
- Publication type:
- Article
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
- Published in:
- Diabetologia, 2019, v. 62, n. 7, p. 1154, doi. 10.1007/s00125-019-4859-4
- By:
- Publication type:
- Article
Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2021.786706
- By:
- Publication type:
- Article
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.662642
- By:
- Publication type:
- Article
A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.626766
- By:
- Publication type:
- Article
Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3371, doi. 10.1111/dom.15678
- By:
- Publication type:
- Article
Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2741, doi. 10.1111/dom.15592
- By:
- Publication type:
- Article
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2128, doi. 10.1111/dom.15518
- By:
- Publication type:
- Article
Front Cover.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. C1, doi. 10.1111/dom.15489
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 924, doi. 10.1111/dom.15387
- By:
- Publication type:
- Article